Français  |  Endo.com

A leader in specialty pharmaceutical innovation

Welcome to Paladin Labs

With headquarters in Montréal, Canada, Paladin Labs Inc. is a leading specialty pharmaceutical company focused on acquiring or licensing emerging pharmaceuticals for the Canadian market.

Their dedicated sales and marketing organization has propelled Paladin to become one of Canada’s pioneers in specialty pharmaceuticals.

Paladin is an operating company of Endo International plc (NASDAQ: ENDP), a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients through excellence in development, manufacturing and commercialization.

An innovative specialty pharmaceutical company

Press Releases

08-Aug-2022
Paladin Labs Announces Health Canada’s Filing Acceptance of Cenobamate Tablets as an Adjunctive Therapy for the Management of Partial-Onset Seizures in Adults with Epilepsy

17-Jan-2022
Paladin Labs Inc. Announces the Launch of Xydalba® (dalbavancin for injection) in Canada

09-Jun-2021
Paladin Labs Inc. Announces Approval of Wakix® (pitolisant) in Canada

12-Apr-2021
ADVANZ PHARMA and Endo Announce Partnership for Paladin Labs to Commercialize Xydalba® (dalbavancin hydrochloride) in Canada

05-Jan-2021
Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada

22-Oct-2020
Envarsus® PA Once-daily Immunosuppressive Therapy for Kidney and Liver Transplant Patients is Now Reimbursed in Ontario, Quebec, Manitoba and Saskatchewan

23-Oct-2019
Movapo® (apomorphine hydrochloride) for Patients with Advanced Parkinson's Disease Now Reimbursed in Most Canadian Provinces

31-Jul-2019
Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada

22-Feb-2019
Paladin Labs Inc. Announces Approval of Envarsus PA^TM (tacrolimus prolonged-release tablets) in Canada

25-Jul-2018
Bioprojet and Endo Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Pitolisant in Canada

23-Apr-2018
Paladin Labs Inc. Announces Launch of New Indication for XIAFLEX® (Collagenase Clostridium Histolyticum), Broadening Its Use to the Treatment of Appropriate Patients with Peyronie's Disease

19-Apr-2018
Paladin Labs Inc. Announces the Launch of Unisom® Snore Relief, the Only Natural Health Product Throat Spray Available in Canada to Help Relieve Symptoms Associated with Snoring

10-Jun-2015
ARIAD and Paladin Announce Commercial Distribution Agreement for Iclusig (Ponatinib) in Canada

9- Feb- 2015
Paladin Labs Announces the Canadian Launch of Zincofax® Spray

19-Aug-2013
Paladin Labs Announces the Canadian Launch of Emtrix®

For complete list of press releases click Here.